| 2026-08-05 | 10-Q | 10.1 | Second Amendment to the License Agreement between the Company and Amunix Pharmaceuticals, Inc., dated June 24, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.3 | First Amendment to the Collaboration and License Agreement between the Company and Astellas US LLC, dated April 15, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.2 | Stock Purchase Agreement between the Company and Astellas US LLC, dated February 19, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.1 | Collaboration and License Agreement between the Company and Astellas US LLC, dated February 19, 2026 |
|---|
| 2026-02-23 | 10-K | 10.67 | NORGINE LICENSE AGREEMENT |
|---|
| 2025-11-05 | 10-Q | 10.1 | First Amendment to the License Agreement between the Company and Amunix Pharmaceuticals, Inc., dated as of April 14, 2025 |
|---|
| 2025-05-08 | 10-Q | 10.2 | Amended and Restated Collaboration and License Agreement by and among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. dated as of March 7, 2025 |
|---|
| 2025-02-27 | 10-K | 10.15 | EX-10.15 CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN |
|---|
| 2025-02-27 | 10-K | 10.13 | EX-10.13 OFFER LETTER (MARK EISNER) |
|---|
| 2025-02-27 | 10-K | 10.12 | EX-10.12 PROMOTION LETTER (VANINA DE VERNEUIL) |
|---|
| 2025-02-27 | 10-K | 10.9 | EX-10.9 DISCRETIONARY BONUS PLAN |
|---|
| 2025-02-27 | 10-K | 10.8 | EX-10.8 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY |
|---|
| 2024-11-04 | 10-Q | 10.4 | Amendment No.3 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No. 75A0122C00081, Amendment No. P00003), dated September 9, 2024 |
|---|
| 2024-11-04 | 10-Q | 10.3 | Amendment No. 2 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No. 75A50122C00081, Amendment No. P00002), dated January 18, 2024 |
|---|
| 2024-11-04 | 10-Q | 10.2 | Offer Letter between the Company and Jason O'Byrne, dated September 6, 2024 |
|---|
| 2024-11-04 | 10-Q | 10.1 | License Agreement between the Company and Amunix Pharmaceuticals, Inc., dated as July 31, 2024 |
|---|
| 2024-05-03 | 10-Q | 10.1 | Letter Agreement between the Company and Glaxo Wellcome UK Limited, dated February 21, 2024. |
|---|
| 2023-11-03 | 10-Q | 10.3 | Amendment No. 1 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No. 75A50122C00081, Amendment No. P00001), dated September 29, 2023. |
|---|
| 2023-11-03 | 10-Q | 10.2 | Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, concerning Pre-exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential (Agreement No. 75A50122C00081), dated September 28, 2022. |
|---|
| 2023-11-03 | 10-Q | 10.1 | Separation Agreement between Vir Biotechnology International GmbH and Johanna Friedl-Naderer, dated September 23, 2023. |
|---|
| 2023-05-08 | 10-Q | 10.4 | Amendment No. 3 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated February 8, 2023. |
|---|
| 2023-05-08 | 10-Q | 10.3 | Amendment No. 2 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated February 8, 2023. |
|---|
| 2023-05-08 | 10-Q | 10.2 | Offer Letter between the Company and Sung Lee, dated February 13, 2023. |
|---|
| 2023-05-08 | 10-Q | 10.1 | Offer Letter between the Company and Marianne De Backer, dated January 19, 2023. |
|---|
| 2023-02-28 | 10-K | 10.17 | Agreement on Transfer of Employment and Amendment of Employment Agreement between Humabs BioMed SA, Vir Biotechnology International GmbH and Johanna Friedl-Naderer, dated December 19, 2022. |
|---|
| 2023-02-28 | 10-K | 10.8 | Non-Employee Director Compensation Policy. |
|---|
| 2022-08-09 | 10-Q | 10.2 | Amendment No. 1 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited dated May 27, 2022. |
|---|
| 2022-08-09 | 10-Q | 10.1 | Termination Agreement between the Company and WuXi Biologics (Hong Kong) Limited dated May 16, 2022. |
|---|
| 2022-05-05 | 10-Q | 10.1 | Employment Agreement between Humabs BioMed SA and Johanna Friedl-Naderer dated December 16, 2021. |
|---|
| 2022-02-28 | 10-K | 10.66 | Lease Agreement between the Company and KRE Exchange Owner LLC, dated December 16, 2021. |
|---|
| 2022-02-28 | 10-K | 10.47 | Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022. |
|---|
| 2022-02-28 | 10-K | 10.46 | Stock Purchase Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022. |
|---|
| 2022-02-28 | 10-K | 10.45 | Amended and Restated Letter Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022. |
|---|
| 2022-02-28 | 10-K | 10.44 | Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated November 5, 2021. |
|---|
| 2022-02-28 | 10-K | 10.43 | Amendment No. 5 to Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2021. |
|---|
| 2021-08-05 | 10-Q | 10.4 | Amendment No. 4 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated June 16, 2021. |
|---|
| 2021-08-05 | 10-Q | 10.3 | Amendment No. 5 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated June 2, 2021. |
|---|
| 2021-08-05 | 10-Q | 10.2 | Definitive Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated May 18, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.6 | Amended and Restated Employment Letter Agreement between the Company and Ann M. Hanly, dated May 4, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.5 | Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.4 | Amendment 1 to Patent License Agreement dated as of March 25, 2020, between the Company and Xencor, Inc., dated February 23, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.3 | Amendment 1 to Patent License Agreement dated as of August 15, 2019, between the Company and Xencor, Inc., dated February 23, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.2 | Stock Purchase Agreement between the Company and Glaxo Group Limited, dated February 14, 2021. |
|---|
| 2021-05-06 | 10-Q | 10.1 | Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated February 14, 2021. |
|---|
| 2021-02-25 | 10-K | 10.61 | Sublease Agreement between the Company and Dropbox, Inc., dated November 4, 2020. |
|---|
| 2021-02-25 | 10-K | 10.51 | Second Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated September 28, 2020. |
|---|
| 2021-02-25 | 10-K | 10.39 | Amendment No. 4 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2020. |
|---|
| 2021-02-25 | 10-K | 10.38 | Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 22, 2020. |
|---|
| 2021-02-25 | 10-K | 10.29 | Amendment No. 1 to License Agreement between the Company and MedImmune, LLC, dated September 1, 2020. |
|---|
| 2021-02-25 | 10-K | 10.24 | Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 23, 2020. |
|---|
| 2021-02-25 | 10-K | 10.8 | Non-Employee Director Compensation Policy. |
|---|
| 2021-02-25 | 10-K | 10.5 | Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan. |
|---|
| 2020-11-10 | 10-Q | 10.4 | Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020. |
|---|
| 2020-11-10 | 10-Q | 10.3 | Employment Letter Agreement between the Company and Steven Rice, dated August 22, 2019. |
|---|
| 2020-08-11 | 10-Q | 10.12 | Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 29, 2020. |
|---|
| 2020-03-26 | 10-K | 10.35 | Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated October 28, 2019. |
|---|
| 2020-03-26 | 10-K | 10.34 | Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 22, 2019. |
|---|
| 2020-03-26 | 10-K | 10.32 | Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated February 24, 2020. |
|---|
| 2020-03-26 | 10-K | 10.31 | Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 18, 2019. |
|---|
| 2020-03-26 | 10-K | 10.22 | Amendment No. 1 to the Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019. |
|---|
| 2020-03-26 | 10-K | 10.20 | Amendment No. 2 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated March 3, 2020. |
|---|
| 2020-03-26 | 10-K | 10.19 | Amendment No. 1 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019. |
|---|
| 2020-03-26 | 10-K | 10.12 | First Amendment to Amended and Restated Employment Letter Agreement between the Company and Michael Kamarck, dated March 13, 2020. |
|---|